MA40428A - Médicament à affinité encapsulé dans un liposome - Google Patents
Médicament à affinité encapsulé dans un liposomeInfo
- Publication number
- MA40428A MA40428A MA040428A MA40428A MA40428A MA 40428 A MA40428 A MA 40428A MA 040428 A MA040428 A MA 040428A MA 40428 A MA40428 A MA 40428A MA 40428 A MA40428 A MA 40428A
- Authority
- MA
- Morocco
- Prior art keywords
- liposome encapsulated
- liposome
- affinity drug
- interior space
- affinity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une composition liposomale anti-folates comprenant un liposome comportant un espace intérieur, un agent antifolate bioactif situé à l'intérieur dudit espace intérieur, un stabilisant stérique fixé à l'extérieur du liposome, et une fraction de ciblage renfermant une protéine ayant une affinité spécifique pour au moins un récepteur de folate, ladite fraction de ciblage étant fixée au stabilisant stérique et/ou à l'extérieur du liposome.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462037597P | 2014-08-14 | 2014-08-14 | |
US201562130493P | 2015-03-09 | 2015-03-09 | |
US201562133265P | 2015-03-13 | 2015-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40428A true MA40428A (fr) | 2016-02-18 |
Family
ID=55304769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040428A MA40428A (fr) | 2014-08-14 | 2015-08-14 | Médicament à affinité encapsulé dans un liposome |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160228573A1 (fr) |
EP (1) | EP3188724B1 (fr) |
JP (1) | JP6825764B2 (fr) |
KR (1) | KR102505508B1 (fr) |
CN (2) | CN106794164A (fr) |
AP (1) | AP2017009766A0 (fr) |
AU (3) | AU2015301462B2 (fr) |
BR (1) | BR112017002767B1 (fr) |
CA (1) | CA2957775C (fr) |
DK (1) | DK3188724T3 (fr) |
EA (1) | EA201790378A1 (fr) |
ES (1) | ES2905498T3 (fr) |
MA (1) | MA40428A (fr) |
MX (1) | MX2017001881A (fr) |
WO (1) | WO2016025882A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
WO2018031979A1 (fr) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Antifolates alpha et gamma-d de polyglutamates et leurs utilisations. |
CA3033077C (fr) * | 2016-08-12 | 2024-06-18 | L.E.A.F. Holdings Group Llc | Antifolates alpha et gamma-d de polyglutamates et leurs utilisations |
WO2018031967A1 (fr) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Antifolates de polyglutamates et leurs utilisations. |
CN106750252B (zh) * | 2016-12-05 | 2018-11-30 | 山东大学齐鲁医院 | 二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000-双叶酸及其制备方法和应用 |
CN110891549A (zh) * | 2017-04-07 | 2020-03-17 | 玛亚实验室公司 | 改善治疗剂的溶解度和生物利用度的方法 |
EP3615005A4 (fr) | 2017-04-28 | 2021-03-10 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Compositions et méthodes d'administration de vaccins |
EP3749319A4 (fr) * | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | Tétrahydrofolates alpha polyglutamés et leurs utilisations |
EP3749314A4 (fr) * | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | Méthotrexate alpha-polyglutamaté et utilisations associées |
US20210338675A1 (en) * | 2018-02-07 | 2021-11-04 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
CA3090387A1 (fr) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Pralatrexate alpha-polyglutamate et utilisations associees |
WO2019157123A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Aminoptérine alpha-polyglutamatée et utilisations associées |
WO2019157140A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Raltitrexed gamma-polyglutamaté et utilisations associées |
CA3090505A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Antifolates gamma-polyglutamates et utilisations associees |
EP3749317A4 (fr) * | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | Pémétrexed alpha-polyglutamaté et utilisations associées |
JP7487107B2 (ja) * | 2018-02-07 | 2024-05-20 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用 |
CN111954530A (zh) * | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | γ聚谷氨酸化培美曲塞及其用途 |
CN111936145A (zh) * | 2018-02-14 | 2020-11-13 | L.E.A.F.控股集团公司 | γ聚谷氨酸化氨甲蝶呤及其用途 |
CA3090875A1 (fr) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Lometrexol gamma polyglutamique et ses utilisations |
CA3090753A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Pralatrexate gamma-polyglutamate et utilisations associees |
CN111971047A (zh) * | 2018-02-14 | 2020-11-20 | L.E.A.F.控股集团公司 | γ聚谷氨酸化四氢叶酸及其用途 |
GB201814959D0 (en) * | 2018-09-14 | 2018-10-31 | Secr Defence | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
EP3965738A1 (fr) * | 2019-05-07 | 2022-03-16 | Universidade do Minho | Procédé de production de liposomes |
WO2020257260A1 (fr) | 2019-06-17 | 2020-12-24 | Massachusetts Institute Of Technology | Formulation de liposomes chargés de peptides et applications associées |
US20230390335A1 (en) * | 2020-10-14 | 2023-12-07 | Georgia Tech Research Corporation | Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
CA2476494C (fr) * | 2002-02-22 | 2010-04-27 | Schering Corporation | Formulations pharmaceutiques d'agents anti-neoplastiques, notamment la temozolomide et procedes de fabrication et d'utilisation associes |
US20100210745A1 (en) * | 2002-09-09 | 2010-08-19 | Reactive Surfaces, Ltd. | Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes |
US8241663B2 (en) * | 2004-03-26 | 2012-08-14 | Terumo Kabushiki Kaisha | Liposome preparation |
US20110022529A1 (en) | 2009-07-22 | 2011-01-27 | Fernando Barsoba | Social network creation using image recognition |
KR101783068B1 (ko) * | 2010-03-19 | 2017-09-28 | 메사추세츠 인스티튜트 오브 테크놀로지 | 지질 소포 조성물 및 사용 방법 |
CA2800693A1 (fr) * | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Apport d'agents therapeutiques a des tissus enflammes au moyen d'agents ciblant le folate |
EP2614084A4 (fr) * | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | Anticorps anti-récepteur bêta de folate humain et leurs procédés d'utilisation |
SI2731591T1 (sl) * | 2011-07-13 | 2021-02-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomi ko-inkapsulirajoči bifosfonat in amfipatično sredstvo |
US20130122096A1 (en) * | 2011-11-14 | 2013-05-16 | Silenseed Ltd. | Compositions for drug delivery and methods of manufacturing and using same |
WO2013084208A2 (fr) * | 2011-12-07 | 2013-06-13 | Universidade Do Minho | Liposomes et procédé de production correspondant |
US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
-
2015
- 2015-08-14 EA EA201790378A patent/EA201790378A1/ru unknown
- 2015-08-14 MA MA040428A patent/MA40428A/fr unknown
- 2015-08-14 BR BR112017002767-4A patent/BR112017002767B1/pt active IP Right Grant
- 2015-08-14 ES ES15832081T patent/ES2905498T3/es active Active
- 2015-08-14 WO PCT/US2015/045353 patent/WO2016025882A2/fr active Application Filing
- 2015-08-14 US US14/826,967 patent/US20160228573A1/en active Pending
- 2015-08-14 AP AP2017009766A patent/AP2017009766A0/en unknown
- 2015-08-14 AU AU2015301462A patent/AU2015301462B2/en active Active
- 2015-08-14 MX MX2017001881A patent/MX2017001881A/es unknown
- 2015-08-14 CN CN201580054566.5A patent/CN106794164A/zh active Pending
- 2015-08-14 CN CN202310777450.0A patent/CN117159470A/zh active Pending
- 2015-08-14 EP EP15832081.2A patent/EP3188724B1/fr active Active
- 2015-08-14 DK DK15832081.2T patent/DK3188724T3/da active
- 2015-08-14 CA CA2957775A patent/CA2957775C/fr active Active
- 2015-08-14 JP JP2017528765A patent/JP6825764B2/ja active Active
- 2015-08-14 KR KR1020177006638A patent/KR102505508B1/ko active IP Right Grant
-
2020
- 2020-05-19 AU AU2020203241A patent/AU2020203241A1/en not_active Abandoned
-
2022
- 2022-03-24 AU AU2022202046A patent/AU2022202046A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020203241A1 (en) | 2020-06-04 |
WO2016025882A2 (fr) | 2016-02-18 |
BR112017002767B1 (pt) | 2023-09-26 |
CA2957775C (fr) | 2022-10-18 |
EP3188724A4 (fr) | 2018-01-24 |
BR112017002767A2 (pt) | 2017-12-19 |
DK3188724T3 (da) | 2022-02-07 |
KR20170046145A (ko) | 2017-04-28 |
EP3188724B1 (fr) | 2021-11-10 |
WO2016025882A8 (fr) | 2017-03-30 |
AU2022202046A1 (en) | 2022-04-14 |
JP2017526744A (ja) | 2017-09-14 |
ES2905498T3 (es) | 2022-04-08 |
AP2017009766A0 (en) | 2017-02-28 |
EA201790378A1 (ru) | 2017-07-31 |
AU2015301462B2 (en) | 2020-02-27 |
EP3188724A2 (fr) | 2017-07-12 |
CA2957775A1 (fr) | 2016-02-18 |
CN117159470A (zh) | 2023-12-05 |
AU2015301462A1 (en) | 2017-03-09 |
MX2017001881A (es) | 2017-09-18 |
US20160228573A1 (en) | 2016-08-11 |
CN106794164A (zh) | 2017-05-31 |
WO2016025882A3 (fr) | 2016-04-07 |
JP6825764B2 (ja) | 2021-02-03 |
KR102505508B1 (ko) | 2023-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40428A (fr) | Médicament à affinité encapsulé dans un liposome | |
PH12017500762A1 (en) | Proflavor delivery particles | |
EP3564281A4 (fr) | Corps en mousse et composition de corps en mousse | |
EP3133435A4 (fr) | Dispositif d'affichage tête-haute et corps mobile ayant un dispositif d'affichage tête-haute monté dans ce dernier | |
ZA202000439B (en) | Liposome compositions comprising weak acid drugs and uses thereof | |
EP3129065A4 (fr) | Administration ciblée d'un médicament faisant appel à des coupleurs fondés sur l'affinité | |
EP3212773A4 (fr) | Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne | |
IL275458A (en) | Therapeutic antibodies to the inner ear by AAV-mediated delivery | |
EP3489936A4 (fr) | Corps d'affichage | |
EP3568143C0 (fr) | Vésicules extracellulaires dérivées de cellules souches mésenchymateuses et leur utilisation médicale | |
EP3470893A4 (fr) | Corps d'affichage | |
EP3347380A4 (fr) | Administration améliorée de médicaments au cerveau | |
IL246408A0 (en) | Preparations for delayed release of proteins and their uses | |
PL4056557T3 (pl) | Pochodne benzoazepiny użyteczne jako leki | |
EP3047834A4 (fr) | Corps distributeur de médicament et unité de distribution de médicament | |
EP3279271A4 (fr) | Composition et corps stratifié | |
EP3197470A4 (fr) | Cis-gnetin h et trans-gnetin h en tant qu'agents thérapeutiques | |
EP3679046A4 (fr) | Composés de phosphaplatine utilisés en tant qu'agents immunomodulateurs et leurs utilisations thérapeutiques | |
TWI559919B (en) | The uses of hydroxyl polymethoxylflavones and/or derivative thereof | |
GB2561864B (en) | Improvements related to the disinfecting of an air space | |
EP3496077A4 (fr) | Corps d'affichage | |
EP3509574A4 (fr) | Utilisation médicale de diterpènes de serrulatane | |
EP3280261A4 (fr) | Agents thérapeutiques anticancéreux | |
PT3606534T (pt) | Derivados de fosfolípidos e sua utilização como medicamentos | |
EP3723559A4 (fr) | Oreillers thérapeutiques personnalisables |